To provide expertise in biologics and vaccines
Piramal Pharma announced an investment of Rs 101.77 crore in Hyderabad-based Yapan Bio augmenting the capabilities of its Contract Development and Manufacturing Organization (CDMO) business, Piramal Pharma Solutions (PPS). PPL holds a 27.78 per cent equity stake in the company as a result of this investment.
As PPS continues to strengthen its capabilities and position itself as a leading CDMO, the acquisition marks a significant addition to PPS’ global capabilities in the development and manufacturing of large molecules for human clinical trials.
Yapan Bio provides process development, scale-up, and cGMP compliant manufacturing of vaccines and biologics/bio-therapeutics, including high containment product classes (up to BSL-2+), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics. Yapan’s FY21 turnover was Rs 12.4 crore. The company has already earned revenues of Rs 11.8 crore for H1FY22 and is poised for fast growth in response to strong market demand.
The investment in Yapan Bio allows PPS to broaden its service offerings in the fast-growing biologics CDMO space. Biologics capabilities can be synergistic with the company’s antibody-drug conjugation capabilities; specifically, for customers who prefer the speed and simplicity benefits of an integrated programme that involves development, manufacturing, conjugation, and fill-finish. PPS currently offers integrated payload, conjugation, fill-finish services, and the addition of anti-body capabilities enhances that offering.
